A Review of Newly Available Humira Biosimilars for Pharmacists

Adalimumab (Humira, AbbVie) has become one of the world’s best-selling drugs for treating various inflammatory conditions spanning dermatology, gastroenterology, and rheumatology since its December 2002 US approval.^1,2

In 2023—over 20 years after Humira’s launch—9 biosimilars were introduced, creating a disruption in the adalimumab market. The arrival of these biosimilars